ALT - Altimmune, Inc.

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes.

Jul 07, 2026 06:16 AM • seekingalpha.com

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026 12:00 AM • gurufocus.com

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.

Jun 26, 2026 02:01 AM • zacks.com

5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

Jun 25, 2026 05:41 AM • zacks.com

Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Jun 12, 2026 08:31 AM • zacks.com

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jun 10, 2026 06:32 AM • seekingalpha.com

Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near

Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company's focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, or MASH.

Jun 10, 2026 05:05 AM • marketbeat.com

ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup

Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.

Jun 08, 2026 09:11 AM • zacks.com

ALT and the Rise of Dual Agonists Targeting Liver Disease

Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.

Jun 08, 2026 09:11 AM • zacks.com

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Jun 08, 2026 08:55 AM • zacks.com

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial

Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.

Jun 04, 2026 07:10 PM • marketbeat.com

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea

May 31, 2026 05:00 AM • gurufocus.com

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result

May 30, 2026 08:00 AM • gurufocus.com

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors

May 28, 2026 07:00 AM • globenewswire.com

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

May 27, 2026 04:30 AM • globenewswire.com

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Concurrent improvement across key non-invasive tests underscores convergence of  pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) of metabolic dysfunction-associated steatohepatitis (MASH) activity and fibrosis.

May 27, 2026 04:00 AM • globenewswire.com

FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir

May 22, 2026 10:00 AM • gurufocus.com

Here's Why You Should Add Altimmune Stock to Your Portfolio Now

ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.

May 22, 2026 09:15 AM • zacks.com

Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil

ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.

May 14, 2026 07:46 AM • zacks.com

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

May 13, 2026 08:40 PM • seekingalpha.com

Altimmune initiated with an Outperform at Leerink

$10.00 (was $3.00)

Thomas Smith · Leerink Partners

Jun 22, 2026 06:30 AM • TheFly

Altimmune upgraded to Neutral from Sell at Goldman Sachs

$2.50 (was $2.89)

Corinne Johnson · Goldman Sachs

Apr 24, 2026 05:10 AM • TheFly

Altimmune initiated with an Overweight at Barclays

$20.00 (was $6.18)

Barclays

Jan 27, 2026 04:11 PM • TheFly

Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report

$12.00 (was $10.23)

Patrick Trucchio · H.C. Wainwright

Apr 02, 2024 02:42 AM • StreetInsider

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

$20.00 (was $9.95)

Goldman Sachs

Dec 01, 2022 12:36 AM • Benzinga

JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26

$26.00 (was $11.12)

JMP Securities

Nov 11, 2022 03:29 AM • Benzinga

Jefferies Maintains Buy on Altimmune, Raises Price Target to $35

$35.00 (was $22.08)

Jefferies

Aug 31, 2022 07:00 AM • Benzinga

Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler

$25.00 (was $18.94)

Yasmeen Rahimi · Piper Sandler

Aug 30, 2022 04:40 PM • TheFly

HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50

$50.00 (was $17.66)

H.C. Wainwright

Aug 17, 2022 02:36 AM • Benzinga